|Animal:||Horses & Ponies|
|Keywords:||acute kidney injury, kidney, SDMA, NGAL, Cystatin C, KIM-1, equine, horse, biomarker|
If you choose to have your horse participate in this clinical trial, and your horse is eligible to be included during your horse’s hospitalization, we will monitor biomarkers of kidney function daily in blood and urine. To do this, we will collect blood and urine daily and repeat the kidney ultrasound on the last day of relevant medication administration.
Your horse will be a part of this study for a minimum of three days and a maximum of the duration of his or her hospitalization in which NSAIDs or aminoglycosides for the primary condition are administered. You will be responsible for covering the costs of your horse’s required hospitalization and associated treatments, but not for the samples collected for this study.
Horses receiving medications that have potential kidney side effects, such as Non-Steroidal Anti-Inflammatory Drugs (Banamine, phenylbutazone, Equioxx) or aminoglycoside antibiotics (gentamicin or amikacin), or oxytetracycline.
Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.